$49 Hims and Hers’ Weight-Loss Pill Shakes Pharma, Not Stocks
Synopsis
On Thursday, February 5, 2026, there was a massive price war in the weight-loss industry when telehealth company Hims & Hers introduced an off-brand version of the buzzy Wegovy pill for $49 a month. The announcement drove the company’s stock way up at first, but after makers of Wegovy made threats to sue, excitement quickly gave way to selloff. Backed by the F.D.A. and its caution against “illegal copycat” drugs, investors are now preparing for an epic legal battle over who will control the future of cheap weight loss medicine.
NEW YORK — The growing market for weight-loss drugs was thrown into turmoil this week when Hims & Hers said it would begin selling a “compounded” version of the blockbuster obesity pill, Wegovy, at an introductory price of only $49 a month. That’s a lot less expensive than the official version from pharmaceutical giant Novo Nordisk, which typically sells for $149 to $199 per month.
The move is a direct challenge to “Big Pharma.” By employing a little-known approach known as compounding, when pharmacies whip up their own versions of a drug’s raw ingredients, Hims & Hers is attempting to bring high-demand weight-loss treatments within reach for millions who can’t get insurance to pay for the brand-name versions.
A “Whiplash” Day for Investors
The news has taken the stock market on a wild ride. Investors were initially excited, sending Hims & Hers shares up 14 per cent when the market opened. Observers viewed the low price as a ploy for the company to attract an enormous new base of customers.
The honeymoon period was short-lived, however. The stock itself had fallen 4% by the end of that day. This abrupt turnabout occurred because investors started to count the huge legal and regulatory mountains the company would have to climb. Seeing a stock fail to hold up on “good news” is often an ominous signal that the yellow-brick road will soon turn very rough, notes one analyst.
Novo Nordisk to Fight Back
The reaction from Novo Nordisk, the firm that produces the authorised Wegovy pill, was swift, and angry. They described the Hims & Hers product as an “unapproved and inauthentic knockoff.” And the Danish drugmaker has already pledged to pursue legal and regulatory remedies to defend its patents, as well as what it refers to as the safety of patients.
It’s not just a fight over money; it comes down to how the drug really works. Novo Nordisk says its pill uses proprietary technology to assist the medication in being absorbed by the body an advantage it says a “copycat” version cannot easily copy. This legal battle could drag on for years, casting a dark shadow over the company’s future profits.
The F.D.A. Warns in No Uncertain Terms
Compounding the company’s problems, when news broke out, the head of the U.S. Food and Drug Administration (FDA), Marty Makary, posted a caution on social media. He didn’t specifically mention Hims & Hers, but said the agency would move “swiftly” against any company that mass-markets “illegal copycat drugs.”
The F.D.A. worries that these off-brand versions have not been subjected to the rigorous safety and quality testing used for the official masks. “If the government decides these compounded pills are an unsafe risk, they could close down the whole program overnight. It’s certainly the case that this regulatory risk is why many professional investors are now shorting the company’s stock.
Key Highlights
- Hims & Hers introduced a compounded weight-loss pill for an introductory price of $49 a month.
- Novo Nordisk has threatened to sue, denouncing the new pill as an “unapproved knockoff.”
- The F.D.A. cautioned that it would take action against “copycat” drugs that have not been evaluated for safety
Follow Inspirepreneur Magazine for the latest American breaking news.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
